Aurora kinase A is a possible target of OSU-03012 to destabilize MYC family proteins

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 901-905

  Silva, Andres ^a   Wang, Jennie ^a   Lomahan, Sarah ^a   Tran, Tuan Anh ^a   Grenlin, Laura ^a   Suganami, Akiko ^b   Tamura, Yutaka ^b   Ikegaki, Naohiko ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

Docking simulation; Neuroblastoma; Phosphorylation; Protein kinase inhibitor; Protein stability

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; AURORA A KINASE; AURORA KINASE INHIBITOR; MYC PROTEIN; TOZASERTIB; AURKA PROTEIN, HUMAN; PIPERAZINE DERIVATIVE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CANCER INHIBITION; COMPUTER MODEL; DRUG POTENCY; DRUG PROTEIN BINDING; IN VITRO STUDY; IN VIVO CULTURE; MOLECULAR DOCKING; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; BRAIN TUMOR; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEUROBLASTOMA; TUMOR CELL LINE;

AURORA KINASE A; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MOLECULAR DOCKING SIMULATION; NEUROBLASTOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MYC; PYRAZOLES; SULFONAMIDES;

EID: 84923068195     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3325     Document Type: Article

References (22)

1. Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27: 289-297, 2009.
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE and Bishop JM: Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224: 1121-1124, 1984. (Pubitemid 14106392)
3. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. New Engl J Med 313: 1111-1116, 1985. (Pubitemid 16216827)
4. Wang LL, Suganuma R, Ikegaki N, et al: Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group. Cancer 119: 3718-3726, 2013.
5. Kucab JE, Lee C, Chen CS, et al: Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7: R796-R807, 2005.
6. Zhu J, Huang JW, Tseng PH, et al: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64: 4309-4318, 2004. (Pubitemid 38802438)
7. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K and Nevins JR: Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14: 2501-2514, 2000.
8. Adhikary S and Eilers M: Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645, 2005. (Pubitemid 41081267)
9. Schulein C and Eilers M: An unsteady scaffold for Myc. EMBO J 28: 453-454, 2009.
10. Marampon F, Ciccarelli C and Zani BM: Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer 5: 31, 2006.
11. Yang H, Liu Q, Cheng GZ, He L, Nicosia, SV and Cheng JQ: Crosstalk between Aurora-A and GSK3β/β-catenin pathways induces c-Myc and cyclin D1. Proc Amer Assoc Cancer Res 46: 5507, 2005.
12. Tang XX, Zhao H, Robinson ME, et al: Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci USA 97: 10936-10941, 2000.
13. Regan PL, Jacobs J, Wang G, et al: Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma. Int J Oncol 38: 105-112, 2011.
14. Torres J, Regan PL, Edo R, et al: Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas. Int J Oncol 37: 983-991, 2010.
15. Cancilla MT, He MM, Viswanathan N, et al: Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry. Bioorg Med Chem Lett 18: 3978-3981, 2008.
16. Harrington EA, Bebbington D, Moore J, et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267, 2004. (Pubitemid 38667616)
17. Yacoub A, Park MA, Hanna D, et al: OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 70: 589-603, 2006. (Pubitemid 44092320)
18. Sawyer TK, Wu JC, Sawyer JR and English JM: Protein kinase inhibitors: breakthrough medicines and the next generation. Expert Opin Investig Drugs 22: 675-678, 2013.
19. Bain J, Plater L, Elliott M, et al: The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315, 2007.
20. Tyler RK, Shpiro N, Marquez R and Eyers PA: VX-680 inhibits Aurora A and Aurora B kinase activity in human cells. Cell Cycle 6: 2846-2854, 2007. (Pubitemid 350277179)
21. Segerstrom L, Baryawno N, Sveinbjornsson B, et al: Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer 129: 2958-2965, 2011.
22. Otto T, Horn S, Brockmann M, et al: Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15: 67-78, 2009.